152 related articles for article (PubMed ID: 11253562)
1. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
Malsch U; Bliesath H; Böther K; Ramm H; Lühmann R
Fortschr Neurol Psychiatr; 2001 Feb; 69(2):86-9. PubMed ID: 11253562
[TBL] [Abstract][Full Text] [Related]
2. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Iizuka J; Fischer R
Nervenarzt; 1986 Mar; 57(3):184-6. PubMed ID: 3515215
[No Abstract] [Full Text] [Related]
3. Budipine in Parkinson's tremor.
Reichmann H
J Neurol Sci; 2006 Oct; 248(1-2):53-5. PubMed ID: 16784759
[TBL] [Abstract][Full Text] [Related]
4. Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings.
Spieker S; Löschmann P; Jentgens C; Boose A; Klockgether T; Dichgans J
Clin Neuropharmacol; 1995 Jun; 18(3):266-72. PubMed ID: 8635185
[TBL] [Abstract][Full Text] [Related]
5. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
[TBL] [Abstract][Full Text] [Related]
6. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
7. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
8. Amantadine in Parkinson's disease: pro and contra.
Greulich W; Fenger E
J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
[TBL] [Abstract][Full Text] [Related]
10. Tremorlytic activity of budipine in Parkinson's disease.
Spieker S; Eisebitt R; Breit S; Przuntek H; Müller D; Klockgether T; Dichgans J
Clin Neuropharmacol; 1999; 22(2):115-9. PubMed ID: 10202609
[TBL] [Abstract][Full Text] [Related]
11. Plasma amantadine concentrations in patients with Parkinson's disease.
Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M
Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813
[TBL] [Abstract][Full Text] [Related]
12. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
13. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
15. Association between amantadine and the onset of dementia in Parkinson's disease.
Inzelberg R; Bonuccelli U; Schechtman E; Miniowich A; Strugatsky R; Ceravolo R; Logi C; Rossi C; Klein C; Rabey JM
Mov Disord; 2006 Sep; 21(9):1375-9. PubMed ID: 16705684
[TBL] [Abstract][Full Text] [Related]
16. Pathological gambling in Parkinson disease is reduced by amantadine.
Thomas A; Bonanni L; Gambi F; Di Iorio A; Onofrj M
Ann Neurol; 2010 Sep; 68(3):400-4. PubMed ID: 20687121
[TBL] [Abstract][Full Text] [Related]
17. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A
Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995
[TBL] [Abstract][Full Text] [Related]
18. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
19. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
Gironell A; Kulisevsky J; Pascual-Sedano B; Flamarich D
Mov Disord; 2006 Apr; 21(4):441-5. PubMed ID: 16229019
[TBL] [Abstract][Full Text] [Related]
20. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Savery F
Dis Nerv Syst; 1977 Aug; 38(8):605-8. PubMed ID: 328244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
